Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors
Summary
Amunix has, since its 2006 launch, licensed to biopharmas technology developed by company co-founder Volker Schellenberger to extend the half-life of some drugs while avoiding triggering an unwanted immune response. Each Amunix candidate is being developed using its proprietary technology, which involves combining a therapeutic protein with a polymer that has been designed to increase its half-life and to hide, or “mask,” what the compound is up to until it reaches the desired target. The company’s lead product candidate, AMX-818, is a T cell engager that it is developing to treat tumors that overexpress HER2, a protein closely associated with an aggressive subtype of breast cancer. Progress that Amunix is making in its preclinical work creating safer, yet potent, T cell engagers is what gave the company the confidence to launch its cytokines program, You adds. CEO You says Amunix didn’t set out to raise $73 million, but its plan to advance drugs based on its technology platform, rather than a single asset, proved especially appealing to investors.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
